A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Seminars in Oncology

• Publication date

  1999-10-01

• Fields of study

  Medicine

• Identifiers
  PMID 10604268
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

  1999cited by this paper
• A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies.

  1999cited by this paper
• Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.

  1999cited by this paper
• Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer.

  1999cited by this paper
• Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.

  1999cited by this paper
• Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials.

  1998cited by this paper
• The dynamics of prostate specific antigen in hormone refractory prostate carcinoma

  1998cited by this paper
• Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.

  1997cited by this paper
• Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines.

  1997cited by this paper
• Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.

  1997cited by this paper
• Bcl2 is the guardian of microtubule integrity.

  1997cited by this paper
• Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

  1996cited by this paper
• Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.

  1996cited by this paper
• Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells.

  1994cited by this paper
• Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.

  1994cited by this paper
• Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.

  1993cited by this paper
• Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines.

  1992cited by this paper
• Evidence for a non‐estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo

  1992cited by this paper
• Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol.

  1991cited by this paper
• Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro.

  1988cited by this paper
• Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells

  1988cited by this paper
• Estramustine‐induced mitotic arrest in two human prostatic carcinoma cell lines du 145 and PC‐3

  1984cited by this paper
• Growth and cell survival following treatment with estramustine nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145).

  1982cited by this paper

• The diffusion of docetaxel in patients with metastatic prostate cancer.

  2015cites this paper
• Castrate Resistant Prostate Cancer: Systemic Chemotherapy and a System Problem

  2015cites this paper
• SOY MEN ’ S HEALTH

  2014cites this paper
• Docetaxel and Cisplatin Regimen for Non-Small-Cell Lung Cancer

  2013cites this paper
• Cancer Chemotherapy Update Docetaxel, Carboplatin, and Trastuzumab (TCH) for HER2-Positive Breast Cancer

  2012cites this paper
• The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.

  2012cites this paper
• Treatment Options in Hormone-Refractory Prostate Cancer

  2012cites this paper
• Gemcitabine, Docetaxel, and Capecitabine (GTX) Regimen for Metastatic Pancreatic Cancer

  2012cites this paper
• Docetaxel, Carboplatin, and Trastuzumab (TCH) for HER2-Positive Breast Cancer

  2012cites this paper
• Docetaxel and Carboplatin (DC) for Ovarian Cancer

  2010cites this paper
• [Low-dose docetaxel, estramustine and dexamethasone combination chemotherapy for hormone-refractory prostate cancer].

  2010cites this paper
• Cancer Chemotherapy Update - Docetaxel and Prednisone (DP) for Advanced Prostate Cancer

  2010cites this paper
• Molecular and traditional chemotherapy: a united front against prostate cancer.

  2010cites this paper
• Docetaxel, Cisplatin, and Fluorouracil (TCF) for Head and Neck Cancers

  2010cites this paper
• FUNCTION OF ANDROGEN RECEPTOR IN PROSTATE CANCER EPITHELIAL MESENCHYMAL TRANSITION AND MICROTUBULE TARGETING

  2010cites this paper
• Evaluation of docetaxel plus estramustine in the treatment of patients with hormone‐refractory prostate cancer

  2009cites this paper
• Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients

  2009cites this paper
• Strategies to Decrease Taxanes Toxicities in the Adjuvant Treatment of Early Breast Cancer

  2009cites this paper
• Docetaxel, Cisplatin, and Fluorouracil (DCF) Regimen for Head, Neck, and Advanced Gastric Cancers

  2008cites this paper
• Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel.

  2008cites this paper
• Gemcitabine and Docetaxel (GD) for Advanced Soft Tissue Sarcomas

  2008cites this paper
• [Chemotherapy for prostate cancer].

  2008cites this paper
• Hormone-Refractory Prostate Cancer: A Rational Approach to Chemotherapy

  2008cites this paper
• Chimiothérapie du cancer de la prostate

  2008cites this paper
• Docetaxel treatment in the elderly patient with hormone refractory prostate cancer

  2007cites this paper
• Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments.

  2007cites this paper
• Chemotherapy for hormone-resistant prostate cancer: Where are we today?

  2007cites this paper
• Taxane-Based Chemotherapy for Prostate Cancer

  2007cites this paper
• New Hope for Patients with Metastatic Hormone-Refractory Prostate Cancer

  2006cites this paper
• Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC Followed by D) in the Treatment of Breast Cancer

  2006cites this paper
• Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) for Breast Cancer

  2006cites this paper
• Combination chemotherapy with estramustine phosphate, ifosfamide and cisplatin for hormone-refractory prostate cancer.

  2006cites this paper
• Phase II study of mitoxantrone and ketoconazole for hormone‐refractory prostate cancer

  2006cites this paper
• Doxorubicin and Docetaxel (AT/AD) for Breast Cancer

  2006cites this paper
• A randomized study of docetaxel and dexamethasone with low‐ or high‐dose estramustine for patients with advanced hormone‐refractory prostate cancer

  2006cites this paper
• An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels.

  2006cites this paper
• Update in the management of patients with hormone-refractory prostate cancer

  2005cites this paper
• Docetaxel for treatment of solid tumours: a systematic review of clinical data.

  2005cites this paper
• Characterization of Prognostic Factors and Efficacy in a Phase-II Study with Docetaxel and Estramustine for Advanced Hormone Refractory Prostate Cancer

  2005cites this paper
• A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer

  2005cites this paper
• The future in advanced prostate cancer: take your partners or is the last dance for me?

  2004cites this paper
• Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients.

  2004cites this paper
• 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.

  2004cites this paper
• A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting

  2003cites this paper
• Combined modality treatment for prostate cancer: role of chemotherapy.

  2003cites this paper
• Chemotherapy for localized, high-risk prostate cancer.

  2003cites this paper
• Ifosfamide in Urologic Cancer

  2003cites this paper
• Perillyl alcohol mediated radiosensitization via augmentation of the Fas pathway in prostate cancer cells

  2003cites this paper
• Cancer Chemotherapy Update

  2003cites this paper
• Controversies in chemotherapy of prostate cancer.

  2002cites this paper
• Highlights of contemporary issues in the medical management of prostate cancer.

  2002cites this paper
• A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer.

  2002cites this paper
• Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro

  2002cites this paper
• Higher doses of mitoxantrone among men with hormone‐refractory prostate carcinoma

  2002cites this paper
• Phase II evaluation of docetaxel plus one‐day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

  2002cites this paper
• Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.

  2001cites this paper
• Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer.

  2001cites this paper
• The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study.

  2001cites this paper
• Docetaxel in prostate cancer.

  2001cites this paper
• Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.

  2001cites this paper
• Systemic treatment and new developments in advanced prostate cancer.

  2001cites this paper
• Weekly high-dose calcitriol and docetaxel in advanced prostate cancer.

  2001cites this paper
• Gemcitabine and cisplatin combination in early-stage non-small-cell lung cancer.

  2001cites this paper
• Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

  2001cites this paper
• Paclitaxel and docetaxel in prostate cancer.

  2001cites this paper
• Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells

  2001cites this paper
• The treatment challenge of hormone-refractory prostate cancer.

  2001cites this paper
• Estramustine potentiates taxane in prostate and refractory breast cancers.

  2001cites this paper
• Docetaxel: assessing a range of activity.

  2001cites this paper
• Chemotherapy for patients with advanced prostate carcinoma

  2000cites this paper
• Recent advances in chemotherapy for advanced prostate cancer

  2000cites this paper
• Colitis and docetaxel-based chemotherapy.

  2000cites this paper
• Chemotherapy for hormone‐refractory prostate cancer: Beauty is in the eye of the beholder

  2000cites this paper
• Vinorelbine and estramustine in androgen‐independent metastatic prostate cancer

  2000cites this paper
• Docetaxel (Taxotere) in hormone-refractory prostate cancer: a new addition to the physicians' toolbag.

  1999cites this paper
• Hormone-refractory prostate cancer: an evolving standard of care.

  1999cites this paper
• Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer

  1999cites this paper